Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 51.2% in April

Posted by Brian Himes on May 17th, 2026

Xenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 7,266 shares, a decrease of 51.2% from the April 15th total of 14,880 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 16,053 shares, the days-to-cover ratio is presently 0.5 days.

Xenetic Biosciences Stock Down 2.3%

Shares of XBIO stock traded down $0.07 during trading hours on Friday, reaching $3.04. The company’s stock had a trading volume of 6,189 shares, compared to its average volume of 14,801. The firm’s 50 day simple moving average is $3.02 and its 200-day simple moving average is $2.63. The company has a market capitalization of $6.96 million, a price-to-earnings ratio of -2.53 and a beta of 2.20. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.81 million during the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Xenetic Biosciences presently has a consensus rating of “Sell”.

View Our Latest Analysis on XBIO

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences as of its most recent filing with the SEC. 15.12% of the stock is currently owned by institutional investors and hedge funds.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.